1. Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population-based study. Lancet Reg Health West Pac 2023;40. [
DOI:10.1016/j.lanwpc.2023.100928]
2. Franchini M, Focosi D, Cruciani M, Joyner MJ, Pirofski L-a, Senefeld JW, et al. Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis. Diseases 2024;12(3):41. [
DOI:10.3390/diseases12030041]
3. Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, et al. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence. Immun Inflamm Dis 2022;10(6):e628. [
DOI:10.1002/iid3.628]
4. Zaboli Mahdiabadi M, Karami C, Saber E, Kamali M, Orandi A, Dadashi A, et al. Effectiveness of Molnupiravir in the Treatment of Patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;33(12):857-67. [
DOI:10.61186/umj.33.12.857]
5. Sharififar S, Dadashi A, Orandi A, Shiri Malekabad E, Khorramnia S, Alazmani Noodeh F. Efficacy and Safety of Favipiravir in Patients with COVID-19: A Review of Systematic Reviews and Meta-Analysis. Stud Med Sci 2022;32(10):782-92. [
DOI:10.52547/umj.32.10.782]
6. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment options for COVID-19: a review. Front Med 2020;7:480. [
DOI:10.3389/fmed.2020.00480]
7. Amani B, Akbarzadeh A, Amani B, Shabestan R, Khorramnia S, Navidi Z, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A Systematic Review and MetaAnalysis. J Med Virol 2023;95(6):e28889. [
DOI:10.1002/jmv.28889]
8. Khorramnia S, Navidi Z, Orandi A, Iravani MM, Orandi A, Malekabad ES, et al. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis. Clin Transplant Res 2024;38(2):136-44. [
DOI:10.4285/ctr.24.0015]
9. Lai C-C, Chen S-Y, Ko W-C, Hsueh P-R. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents 2021;57(4):106324. [
DOI:10.1016/j.ijantimicag.2021.106324]
10. Ahorsu DK, Lin C-Y. The effect of COVID-19 vaccine acceptance, intention, and/or hesitancy and its association with our health and/or important areas of functioning. MDPI; 2023. p. 368. [
DOI:10.3390/vaccines11020368]
11. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22(9):1293-302. [
DOI:10.1016/S1473-3099(22)00320-6]
12. Atanasov V, Barreto N, Whittle J, Meurer J, Weston BW, Luo Q, et al. Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage. Vaccines 2023;11(2):379. [
DOI:10.3390/vaccines11020379]
13. Yan Z, Yang M, Lai C-L. COVID-19 vaccinations: a comprehensive review of their safety and efficacy in special populations. Vaccines 2021;9(10):1097. [
DOI:10.3390/vaccines9101097]
14. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HH, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 2020;8(8):e1003-e17. [
DOI:10.1016/S2214-109X(20)30264-3]
15. Stadler E, Burgess MT, Schlub TE, Khan SR, Chai KL, McQuilten ZK, et al. Monoclonal antibody levels and protection from COVID-19. Nat Commun 2023;14(1):4545. [
DOI:10.1038/s41467-023-40204-1]
16. van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv 2023;7(11):2645-55. [
DOI:10.1182/bloodadvances.2022009578]
17. Cimellaro A, Addesi D, Cavallo M, Spagnolo F, Suraci E, Cordaro R, et al. Monoclonal antibodies and antivirals against SARS-CoV-2 reduce the risk of long COVID: a retrospective propensity score-matched case-control study. Biomedicines 2022;10(12):3135. [
DOI:10.3390/biomedicines10123135]
18. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020;369(6506):1010-4. [
DOI:10.1126/science.abd0827]
19. Falcone M, Tiseo G, Valoriani B, Barbieri C, Occhineri S, Mazzetti P, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther 2021;10(4):2479-88. [
DOI:10.1007/s40121-021-00525-4]
20. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384(3):229-37. [
DOI:10.1056/NEJMoa2029849]
21. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med 2021;13(593):eabf1906. [
Google Scholar]
22. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19. Open Forum Infect Dis 2021;8(7):ofab331. [
DOI:10.1093/ofid/ofab331]
23. Farcy DA, Dalley MT, Miro G, Swalley P, Sherman D, Nash J, et al. A comparison of SARS-COV-2 neutralizing antibody therapies in high-risk patients with mild to moderate COVID-19 disease at a single academic hospital. J Emerg Med 2022;62(1):83-91. [
DOI:10.1016/j.jemermed.2021.07.025]
24. McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, Albin D, et al. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. Contemp Clin Trials 2022;119:106822. [
DOI:10.1016/j.cct.2022.106822]
25. Balasubramanian P, Berto CG, Hassan E, Valentine N, De Vos G, Coyle C, et al. Outcomes in Patients with Mild COVID-19 Treated With Casirivimab and Imdevimab or Bamlanivimab-A Single-Center Retrospective Cohort Study in the Bronx. Infect Dis Clin Pract 2022;30(3):e1128. [
DOI:10.1097/IPC.0000000000001128]
26. Chilimuri S, Mantri N, Gurjar H, Youthjug KA, Sun H, Gongati S, et al. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: a South-Bronx experience. J Nat Med Assoc 2022;113(6):701-5. [
DOI:10.1016/j.jnma.2021.08.036]
27. Cooper MH, Christensen PA, Salazar E, Perez KK, Graviss EA, Nguyen D, et al., editors. Real-world assessment of 2879 COVID-19 patients treated with monoclonal antibody therapy: a propensity score-matched cohort study. Open Forum Infect Dis 2021;8(11): ofab512. [
DOI:10.1093/ofid/ofab512]
28. Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, et al. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. J Infect Dis 2021;224(8):1278-86. [
DOI:10.1093/infdis/jiab377]
29. San Filippo S, Crovetto B, Bucek J, Nahass RG, Milano M, Brunetti L. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis. Open Forum Infect Dis 2022;9(4):ofac080. [
DOI:10.1093/ofid/ofac080]
30. Savoldi A, Morra M, De Nardo P, Cattelan AM, Mirandola M, Manfrin V, et al. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Eur J Clin Microbiol Infect Dis 2022;41(7):1065-76. [
DOI:10.1007/s10096-022-04464-x]
31. Voelker D, Jerath M. Monoclonal antibody infusion for COVID-19 infection: results from a tertiary referral center. J Allergy Clin Immunol 2022;149(2):AB194. [
DOI:10.1016/j.jaci.2021.12.639]
32. Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021;184(9):2316-31. [
DOI:10.1016/j.cell.2021.03.029]
33. Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: A Systematic Review and Network Meta-Analysis. Infection 2023;51(1):21-35. [
DOI:10.1007/s15010-022-01825-8]
34. Amani B, Khodavirdilou L, Rajabkhah K, Moghaddam VK, Akbarzadeh A, Amani B. Efficacy and safety of bamlanivimab in patients with COVID-19: A Systematic Review and Meta-Analysis. World J Virol 2024;13(1). [
DOI:10.5501/wjv.v13.i1.88660]
35. Orandi A, Mohajeri M, Mansouri M, Salajegheh M, Jalili M, Esmaiil Zali M, et al. Clinical Effectiveness of Casirivimab and Imdevimab Compared with Standard of Care in COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2024;34(11):727-41. [
DOI:10.61186/umj.34.11.8]
36. Khorramnia S, Jalili M, Salajegheh M, Mansouri M. Efficacy of Bamlanivimab Compared to Standard Care in Treatment of the Patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;34(8):461-70. [
DOI:10.61186/umj.34.8.461]
37. Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, et al. A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2. Infect Dis Ther 2021;10(4):1933-47. [
DOI:10.1007/s40121-021-00515-6]
38. Wicaksono IA, Suhandi C, Elamin KM, Wathoni N. Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial. Heliyon 2023. [
DOI:10.1016/j.heliyon.2023.e22839]
39. Gao M, Ao G, Hao X, Xie B. Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis. J Infect 2023;87(1):82. [
DOI:10.1016/j.jinf.2023.04.019]
40. Tai Y-L, Lee M-D, Chi H, Chiu N-C, Lei W-T, Weng S-L, et al. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. PeerJ 2023;11:e15344. [
DOI:10.7717/peerj.15344]
41. Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: a systematic review and meta‐analysis of randomized controlled trials. J Med Virol 2022;94(5):2222-9. [
DOI:10.1002/jmv.27623]
42. Zuo L, Ao G, Wang Y, Gao M, Qi X. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: a systematic review and meta-analysis. J Infect 2022;84(2):248. [
DOI:10.1016/j.jinf.2021.09.003]
43. Hwang Y-C, Lu R-M, Su S-C, Chiang P-Y, Ko S-H, Ke F-Y, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci 2022;29(1):1. [
DOI:10.1186/s12929-021-00784-w]
44. Siemieniuk RA, Bartoszko JJ, Martinez JPD, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Br Med J 2021;374. [
Google Scholar]
45. McConnell D, Harte M, Walsh C, Murphy D, Nichol A, Barry M, et al. Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis. Sci Rep 2022;12(1):17561. [
DOI:10.1038/s41598-022-22431-6]
46. Plichta J, Kuna P, Panek M. Monoclonal antibodies as potential COVID-19 therapeutic agents. COVID 2022;2(5):599-620. [
DOI:10.3390/covid2050045]
47. Taylor PC, Adams AC, Hufford MM, De La Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 2021;21(6):382-93. [
DOI:10.1038/s41577-021-00542-x]